Clopidogrel plus aspirin [acetylsalicylic acid] inhibits the early activation of platelets and reduces the prevalence of major adverse cardiovascular events

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1552, 2006-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rationale for a Trial of Low-Dose Aspirin for the Primary Prevention of Major Adverse Cardiovascular Events and Vascular Dementia in the Elderly: Aspirin in Reducing Events in the Elderly (ASPREE)

By Nelson M.R.   Reid C.M.  

Drugs & Aging, Vol. 20, Iss. 12, 2003-01 ,pp. : 897-903

Adis International

Access to resources Recommend Favorite

Clopidogrel + aspirin beneficial for cardiovascular disease

By  

Inpharma, Vol. 1, Iss. 1602, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Clopidogrel plus aspirin demonstrates platelet inhibition in congestive heart failure (CHF), regardless of major clinical characteristics of the disease

By  

Inpharma, Vol. 1, Iss. 1582-1583, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Thiazolidinedione treatment is not associated with an increased risk of major adverse cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1643, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Aspirin resistance reduces response to clopidogrel after PCI

By  

Inpharma, Vol. 1, Iss. 1527, 2006-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite